Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Featured Practice Guidelines
    • AASLD updated...

    AASLD updated guidelines for management of HCV infection

    Written by Dr. Kamal Kant Kohli Kohli Published On 2018-02-14T19:01:42+05:30  |  Updated On 14 Feb 2018 7:01 PM IST
    AASLD updated guidelines for management of HCV infection

    The AASLD/IDSA HCV Guidance Panel has updated the guidelines for management of HCV infection which have been Published in Hepatology. The speed of hepatitis C virus (HCV) drug development in recent years has accelerated dramatically. The practitioners require access to the most up-to-date data and advice from experienced experts in order to benefit patients by these impressive advances. approval of the fixed-dose combination drug sofosbuvir-velpatasvir for the treatment of HCV infection.The fixed dose combination is available as Sofosbuvir 400 mg plus Velpatasvir 100 mg q24h dosage.


    Summary of Updated Recommendations:


    Successful hepatitis C treatment is achievable in nearly all infected patients and is reflected by a sustained virological response (SVR), defined as the continued absence of detectable HCV RNA for 12 or more weeks after completion of therapy.




    1. All treatment-naïve persons with HCV genotypes 1–6 without cirrhosis or with compensated cirrhosis:


    Daily fixed-dose combination of sofosbuvir-velpatasvir for 12 weeks




    1. In patients in whom previous treatment has failed:

    2. HCV Genotypes 1a, 1b, 2, 3, 4, 5, and 6 with previous failure with all regimens (except genotype 1, as mentioned below): fixed dose combination of sofosbuvir-velpatasvir for 12 weeks is recommended.

    3. HCV Genotype 1 with simeprevir-sofosbuvir and HCV-NS5A inhibitor treatment-experienced patients:

      • Deferral of treatment in recommended in whom prior treatmen with HCV protease inhibitor, who do not have cirrhosis and do not have reasons for urgent retreatment.

      • Testing for resistance-associated variants that confer decreased susceptibility to NS3 protease inhibitors and to NS5A inhibitors is recommended for patients with HCV genotype 1 infection, regardless of subtype, in whom prior treatment with the HCV protease inhibitor simeprevir plus sofosbuvir has failed (no prior NS5A treatment), who have compensated cirrhosis, or have reasons for urgent retreatment. The specific drugs used in the retreatment regimen should be tailored to the results of this testing as described below.

      • When using nucleotide-based (eg, sofosbuvir) dual DAA therapy a treatment duration of 24 weeks is recommended, and weight-based ribavirin, unless contraindicated, should be added.

      • If available, nucleotide-based (eg, sofosbuvir) triple or quadruple DAA regimens may be considered. In these settings treatment duration ranges from 12 weeks to 24 weeks (see text), and weight-based ribavirin, unless contraindicated, are recommended.





    1. Decompensated cirrhosis in HCV Genotypes 1 and 4 infection:



    1. Moderate to severe hepatic impairment, Child-Turcot-Pugh (CTP) class B or C, who may or may not be eligible candidates for liver transplantation, including those with HCC:

      • Daily fixed-dose combination of sofosbuvir-velpatasvir with weight-based ribavirin (low intial dose of 600 mg is recommended in CTP class C patients) for 12 weeks



    2. For those who are ribavirin-ineligible:

      • Daily fixed-dose combination of sofosbuvir-velpatasvir for 24 weeks



    3. In whom prior sofosbuvir-based treatment has failed:

      • Daily fixed dose combination of sofosbuvir-velpatasvir with weight-based ribavirin (initial low-dose of ribavirin of 600 mg in persons with CTP class C) for 24 weeks





    1. Decompensated cirrhosis in HCV genotypes 2 and 3 infection: Moderate of severe hepatic impairment, CTP class B or C, and who may or may not be candidate for liver transplantation, including those with HCC:


    Daily fixed-dose combination of sofosbuvir-velpatasvir with weight-based ribavirin for 12 weeks




    1. Patients with Renal Impairment:


    Mild to Moderate Renal Impairment (CrCl 30–80 mL/min): No dose adjustment is required for the use of fixed-dose combination of sofosbuvir-velpatasvir for treatment or retreatment




    1. Patients with HIV/HCV coinfection


    Daily fixed dose combination of sofosbuvir-velpatasvir can be used with most antivirals, but SHOULD NOT be used with efavirenz, etravirine, or nevirapine.




    • Because velpatasvir increases tenofovir levels, when given as tenofovir disoproxil fumarate (TDF), concomitant use mandates consideration of renal function and should be avoided in those with CrCl below 60 mL/min.

    • In patients with CrCl >60 mL/min concomitant dosing of velpatasvir and TDF with ritonavir-boosted or cobicistat-boosted regimens did not result in renal toxicity in 56 subjects.

    • Renal monitoring is recommended during the dosing period.

    • Tenofovir alafenamide (TAF) may be an alternative to TDF during sofosbuvir-velpatasvir treatment for patients who take cobicistat or ritonavir as part of their antiretroviral therapy.


    For further reference log on to :


    http://onlinelibrary.wiley.com/doi/10.1002/hep.27950/pdf


    CirrhosisHCV infectionHCV protease inhibitorHepatitis C virusHepatologyJournal of HepatologyribavirinTenofovir alafenamidetenofovir disoproxil fumarate

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok